November 2, 2022 


Dear OMIC Insureds: 

An increasing number of ophthalmologists treating retinal conditions with intravitreal anti-VEGF agents are being asked by health systems and hospitals to utilize bevacizumab biosimilar drugs. Both the AAO (2022) and CMS (2021) have issued statements recommending against the use of off-label bevacizumab biosimilars to treat ocular conditions due to insufficient data regarding long-term efficacy and safety profiles. OMIC supports these statements and strongly recommends against the use of bevacizumab biosimilar drugs for intravitreal injection, as well as off-label use of all biosimilars for the treatment of ROP until further clinical data becomes available.

If you have questions about this topic or would like to have a confidential risk management consultation, please email riskmanagement@omic.com or 1-800-562-6642, enter 4 for OMIC Risk Management.

Sincerely,


Michael C. Tigani, MD
Chair, OMIC Risk Management Committee